Mettler-Toledo International Valuation
Is MTD * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MTD * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MTD * (MX$25433) is trading above our estimate of fair value (MX$15520.45)
Significantly Below Fair Value: MTD * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MTD *?
Other financial metrics that can be useful for relative valuation.
What is MTD *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$32.07b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 9x |
Enterprise Value/EBITDA | 29.3x |
PEG Ratio | 5x |
Price to Earnings Ratio vs Peers
How does MTD *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 41.4x | ||
IQV IQVIA Holdings | 30.3x | 12.9% | US$41.8b |
WST West Pharmaceutical Services | 42.8x | 10.8% | US$24.5b |
A Agilent Technologies | 36.2x | 9.0% | US$45.0b |
LONN Lonza Group | 56.3x | 20.7% | CHF36.8b |
MTD * Mettler-Toledo International | 41.2x | 8.3% | Mex$32.1b |
Price-To-Earnings vs Peers: MTD * is good value based on its Price-To-Earnings Ratio (41.2x) compared to the peer average (41.4x).
Price to Earnings Ratio vs Industry
How does MTD *'s PE Ratio compare vs other companies in the Global Life Sciences Industry?
Price-To-Earnings vs Industry: MTD * is expensive based on its Price-To-Earnings Ratio (41.2x) compared to the Global Life Sciences industry average (31.8x).
Price to Earnings Ratio vs Fair Ratio
What is MTD *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 41.2x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate MTD *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$25,000.00 | Mex$21,976.65 -12.1% | 15.6% | Mex$26,532.17 | Mex$14,684.47 | n/a | 10 |
May ’25 | Mex$21,280.00 | Mex$20,368.96 -4.3% | 12.3% | Mex$23,303.74 | Mex$15,078.89 | n/a | 11 |
Apr ’25 | n/a | Mex$20,158.00 0% | 12.0% | Mex$23,275.99 | Mex$15,060.94 | n/a | 11 |
Mar ’25 | n/a | Mex$20,158.00 0% | 12.0% | Mex$23,275.99 | Mex$15,060.94 | n/a | 11 |
Feb ’25 | Mex$20,879.25 | Mex$19,772.06 -5.3% | 14.2% | Mex$25,685.64 | Mex$15,155.80 | n/a | 11 |
Jan ’25 | n/a | Mex$19,248.65 0% | 14.8% | Mex$25,604.21 | Mex$15,107.75 | n/a | 12 |
Dec ’24 | Mex$18,975.91 | Mex$19,157.46 +1.0% | 13.6% | Mex$24,935.65 | Mex$15,133.36 | n/a | 12 |
Nov ’24 | n/a | Mex$22,577.98 0% | 16.1% | Mex$27,627.60 | Mex$15,984.41 | n/a | 12 |
Oct ’24 | n/a | Mex$22,077.83 0% | 12.5% | Mex$25,372.41 | Mex$14,679.63 | n/a | 12 |
Sep ’24 | Mex$20,236.00 | Mex$22,077.83 +9.1% | 12.5% | Mex$25,372.41 | Mex$14,679.63 | n/a | 12 |
Aug ’24 | n/a | Mex$22,077.83 0% | 12.5% | Mex$25,372.41 | Mex$14,679.63 | n/a | 12 |
Jul ’24 | n/a | Mex$25,446.58 0% | 13.1% | Mex$29,138.64 | Mex$15,446.99 | n/a | 12 |
Jun ’24 | Mex$23,490.51 | Mex$25,446.58 +8.3% | 13.1% | Mex$29,138.64 | Mex$15,446.99 | n/a | 12 |
May ’24 | Mex$26,720.61 | Mex$26,943.33 +0.8% | 14.9% | Mex$30,559.54 | Mex$14,920.25 | Mex$21,280.00 | 12 |
Apr ’24 | n/a | Mex$27,595.18 0% | 14.5% | Mex$31,593.99 | Mex$15,425.30 | n/a | 12 |
Mar ’24 | Mex$26,774.45 | Mex$27,595.18 +3.1% | 14.5% | Mex$31,593.99 | Mex$15,425.30 | n/a | 12 |
Feb ’24 | Mex$25,265.00 | Mex$26,325.81 +4.2% | 15.5% | Mex$32,098.89 | Mex$15,671.81 | Mex$20,879.25 | 12 |
Jan ’24 | n/a | Mex$26,092.97 0% | 12.7% | Mex$29,696.10 | Mex$16,431.84 | n/a | 12 |
Dec ’23 | n/a | Mex$24,838.77 0% | 13.7% | Mex$29,126.55 | Mex$16,116.69 | Mex$18,975.91 | 11 |
Nov ’23 | Mex$25,265.04 | Mex$25,577.81 +1.2% | 14.2% | Mex$29,978.25 | Mex$16,587.97 | n/a | 11 |
Oct ’23 | Mex$30,826.80 | Mex$25,704.15 -16.6% | 13.8% | Mex$29,924.40 | Mex$16,558.17 | n/a | 11 |
Sep ’23 | Mex$30,826.80 | Mex$26,152.80 -15.2% | 15.0% | Mex$30,576.15 | Mex$15,695.76 | Mex$20,236.00 | 11 |
Aug ’23 | Mex$30,826.80 | Mex$26,152.80 -15.2% | 15.0% | Mex$30,576.15 | Mex$15,695.76 | n/a | 11 |
Jul ’23 | Mex$30,826.80 | Mex$25,779.28 -16.4% | 15.1% | Mex$29,793.45 | Mex$15,293.97 | n/a | 10 |
Jun ’23 | Mex$30,826.80 | Mex$25,779.28 -16.4% | 15.1% | Mex$29,793.45 | Mex$15,293.97 | Mex$23,490.51 | 10 |
May ’23 | n/a | Mex$28,033.71 0% | 18.4% | Mex$33,325.38 | Mex$15,551.84 | Mex$26,720.61 | 10 |
Analyst Forecast: Target price is lower than the current share price.